Could Dyax Corp.(NASDAQ:DYAX), Celldex Therapeutics, Inc.(NASDAQ:CLDX), or Baxter International Inc.(NYSE:BAX) Be The Next Biotech Breakout?

Posted by admin October 22, 2014 0 Comment 669 views


New York, NY – GDP INSIDER  –  10/22/2014.

This article discusses three biotechnology companies: Dyax Corp.(NASDAQ:DYAX), Celldex Therapeutics, Inc.(NASDAQ:CLDX), or Baxter International Inc.(NYSE:BAX)

Dyax Corp.(NASDAQ:DYAX) is a Massachusetts-based biotechnology company that develops treatments for angioedemas. The company’s products include KALBITOR and DX-2930, the latter of which is currently under development. Dyax Corp. currently has a market capitalization of over $1.25 billion and $136.21 million tradeable shares. The company will be releasing its third quarter financial results after the markets close on Oct. 28th, 2014. Additionally, Dyax Corp. will also be hosting a conference call and webcast at 5PM EST to discuss the results.

Is Dyax Corp. A Smart Investment? View Our Free DYAX Analysis.

Celldex Therapeutics, Inc.(NASDAQ:CLDX) released a SEC form 8-K on Oct. 20th detailing its entrance into  material definitive agreement with BIOSYN Corporation. According to the deal, BIOSYN will manufacture and supply its hemocyanin product formulations, including keyhole limpet hemocyanin, to Celldex. The New Jersey-based biotechnology company develops novel therapeutics for human health care in the United States. Celldex Therapeutics currently has a market capitalization of over $1.25 billion and 89.4 million tradeable shares.

Could Celldex Be An Option For Day Traders? Receive A Free CLDX Analysis.

Baxter International Inc.(NYSE:BAX) had a bid price of $65.26 x 500 and an offer price of $73.25 x 1,500 on Oct. 21st, 2014, figures which suggest the company’s value could fluctuate in the future. On Oct. 16th, the company reported its third quarter financial results. The figures, which exceeded Baxter’s guidance, included a net income of $468 million and $0.86 per common share. That being said, those figures are $76 million and $0.13 per common share less than its results for the same period during the previous fiscal year.

How Might Baxter’s Results Report Affect Its Future Trading Value? Take A Look At Our Free BAX Analysis.

About HotStockGains

HotStockGains.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word BREAKOUT to 555888 from your cell phone.

Additionally, HotStockGains free newsletter provides market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks.

Disclosure:  HotStockGains is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit http://hotstockgains.com/disclaimer/ for complete risks and disclosures.


Write Your Comment